Heparin-induced thrombocytopenia is a drug-induced immunohematologic adverse reaction where treatment approaches emphasizing thrombin inhibition are recommended based on emerging consensus.
Highlights the emerging consensus on HIT management, specifically the rationale for using thrombin inhibitors like danaparoid sodium and hirudin.
Summary Heparin-induced thrombocytopenia (HIT) is a drug-induced, immunoglobulin-mediated thrombocytopenic disorder that is important for at least three reasons. First, it is a relatively common drug-induced immunohematologic adverse reaction. Second, it is frequently complicated by life- and limb-threatening thrombotic complications. And third, there remains uncertainty about the optimal treatment approach for these patients. Recently, there has emerged increasing consensus on such important issues as the frequency, pathogenesis, and diagnostic testing, which we will summarize here. Further, a greater appreciation of the activation of the coagulation pathways in this syndrome indicate a rationale to treatment approaches that emphasize thrombin inhibition (eg. danaparoid sodium; hirudin and its analogues).
Warkentin et al. (Thu,) conducted a review in Heparin-induced thrombocytopenia (HIT). Thrombin inhibition (e.g., danaparoid sodium; hirudin and its analogues) was evaluated. Heparin-induced thrombocytopenia is a drug-induced immunohematologic adverse reaction where treatment approaches emphasizing thrombin inhibition are recommended based on emerging consensus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: